大行評級|建銀國際:上調康方生物目標價至90港元 續列爲生物科技行業首選
建銀國際發表研究報告指,康方生物去年全年及下半年經調整淨虧損錄4.35億及1.88億元,勝預期,受到銷量增長疲弱的拖累,收入表現略遜預期。但憧憬康方生物今年可能首次實現扭虧爲盈,預測錄得淨利潤2300萬元及經調整淨利潤1.03億元。建銀國際維持康方生物爲生物科技行業的首選股,維持“跑贏大市”評級,目標價由85港元上調至90港元。雖然AK104及AK112已被納入國家醫保藥品目錄,但考慮到公司的銷售團隊需要更多時間來提升銷量,該行將康方生物今明兩年收入預測下調6%及4%,2026年經調整淨利潤預測則上調3%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.